|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
|
|
|
|
|
|
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
DILTIAZEM INHIBIT CYP-450 ENZYME THUS REDUCING THE CLEARANCE OF THE DRUG, HENCE DOSE OF THE DRUG SHOULD BE REDUCED
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
ERGOTAMINE INHIBITS METABOLISM OF THE DRUG
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
CONCURRENT USE WITH DRUGS CAUSING TORSADES PHENOMENON OR PROLONGED Q-TC INTERVAL MAY LEAD TO INCREASED CHANCES OF CARDIAC ARRHYTHMIAS
|
INCREASED RISK OF NEPHROTOXICITY
|